ATHA — Athira Pharma Inc
NASDAQ · Healthcare · Biotechnology
Athira Pharma Inc (ATHA) is a biotechnology company listed on NASDAQ. It is led by Mark J. Litton M.B.A., Ph.D., based in 18706 North Creek Parkway, Bothell, WA, United States, 98011, with about 26 employees. Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Net income was -$22.7M. ATHA currently screens at market cap $26.6M.
Use this ATHA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATHA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATHA SEC filings page. Lician reads the product cache first so this HTML stays unique to Athira Pharma Inc even when a live quote feed is slow.
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
ATHA Key Statistics
Market Cap
$26.62M
EPS
-$2.52
Revenue
$0.00
Net Income
-$96.94M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
26
ATHA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$96.94M | -$117.67M | -$95.64M | -$54.85M |
| EPS (Diluted) | -$2.52 | -$3.09 | -$2.53 | -$1.49 |
Total Assets
$58.78M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$48.44M
Operating Cash Flow
-$97.17M
Free Cash Flow
$0.00
Athira Pharma Inc Company Information
- President, CEO & Director
- Mark J. Litton M.B.A., Ph.D.
- Headquarters
- 18706 North Creek Parkway, Bothell, WA, United States, 98011
- Website
- www.athira.com
- Phone
- 425 620 8501
- IPO / Founded
- 2020-09-18
- Sector
- Healthcare
- Industry
- Biotechnology